Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Currency in USD	2025
Operating Income	10.02 Billion
Income Before Tax	9.80 Billion
Income Tax Expense	1.29 Billion
Net Income	8.51 Billion
Eps	6.84
Epsdiluted	6.78
Weighted Average Shs Out	1.24 Billion
Weighted Average Shs Out Dil	1.25 Billion
Research And Development Expenses	N/A
Selling General And Administrative Expenses	5.77 Billion
Depreciation And Amortization	2.76 Billion
Interest Expense	1.02 Billion
Interest Income	349.00 Million
Net Interest Income	-675 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	23.21 Billion
Ebitda	14.46 Billion
Source	edgar
Ebit	10.82 Billion

Gilead Sciences, Inc. Annual Reports (10-K)